82 indexable Neurology companies headquartered in Germany, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $934.9M across 30 funded companies, including 1 unicorn.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Vivoryon
Developer of therapeutic agents for age related disorders |
$112.2M | — | Public | Post IPO Oct 2025 | 100 | 1997 | ↑ Active |
| 2 |
MODAG
Developer of therapeutics and diagnostics for neurodegenerative diseases |
$16.3M | — | Series A | Grant (prize money) Dec 2025 | 12 | 2013 | ↑ Active |
| 3 |
Evanium
Developer of selective alcohol antagonist |
$2.6M | — | Seed | Seed Apr 2026 | 5 | 2017 | ↑ Active |
| 4 |
brainjo
AI based plafrom providing cognitive training |
$2.4M | — | Seed | Seed Apr 2026 | — | 2019 | ↑ Active |
| 5 |
Insellar
Developer of minimally invasive brain interfaces for mental health treatment |
$468.7K | — | Seed | Seed Apr 2026 | — | 2025 | ↑ Active |
| 6 |
NeuroCare Group
Provider of noninvasive neurotechnology and personalized mental healthcare platform |
$17M | — | Series B | Series B Feb 2025 | 14 | 2015 | ↑ Active |
| 7 |
Protembis
Manufacturer of cerebral protection device |
$42.5M | — | Public | Venture Debt Jul 2024 | 3 | 2013 | ↑ Active |
| 8 |
Nuuron
Developer of a digital drug to treat Alzheimer's disease |
$3.8M | — | Seed | Seed Oct 2024 | — | 2023 | ↑ Active |
| 9 |
ATAI
Unicorn Biopharmaceutical company accelerating the development of mental health treatments |
$386.7M | $2B as of 2021 |
Public | Mar 2021 | 119 | 2018 | — |
| 10 |
HMNC Brain Health
Developer of targeted therapies for depression and other neuropsychiatric disorders |
$41.5M | — | Series B | Series B Oct 2022 | 18 | 2010 | — |
| 11 |
CorTec
Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies |
$21.6M | — | Series C | Grant (prize money) Feb 2023 | 68 | 2010 | — |
| 12 |
Probiodrug
Developing new therapeutic products for the treatment of Alzheimer’s disease |
$86.9M | — | Public | Post IPO Apr 2019 | — | 1997 | — |
| 13 |
veriNOS pharmaceuticals
Developer of therapeutics for retina and brain diseases |
$62.7M | — | Series G | Series G Jul 2019 | 5 | 1998 | — |
| 14 |
Sapiens Neuro
Developer of brain stimulation device to treat neurodegenerative disorders |
$55.9M | — | Acquired | Series C Nov 2013 | 59 | 2011 | — |
| 15 |
Affectis
Developer of drugs for the treatment of neurodegenerative and neuroinflammatory diseases |
$25M | — | Deadpooled | Series D Mar 2010 | — | 2004 | — |
| 16 |
PROSION
Developer of precision medicine technology for cancer treatment |
$5.5M | — | Funding Raised | Grant (prize money) Apr 2022 | 10 | 2020 | — |
| 17 |
Algiax
Speciality company that develops new products for nervous system diseases with focus on neuropathic pain |
$11.6M | — | Series A | Series A Dec 2019 | 4 | 2011 | — |
| 18 |
Precisis
Portfolio of devices and tools for neurological surgery |
$2.8M | — | Funding Raised | Grant (prize money) 2022 | 14 | 2002 | — |
| 19 |
KeyNeurotek Pharmaceuticals
Develops drugs for degenerative disorders and autoimmune diseases |
$11.1M | — | Deadpooled | Series C Apr 2009 | — | 2000 | — |
| 20 |
Neuway Pharma
Therapies for the treatment of brain diseases using its proprietary CNS drug delivery platform |
$7.2M | — | Public | Grant (prize money) Jun 2016 | 18 | 2014 | — |
| 21 |
BioCrea
CNS-focused drug development company with a proprietary compound library & patient-derived IPSC (induced pluripotent stem cell) screening platform |
$6.8M | — | Deadpooled | Series A Nov 2010 | — | 2010 | — |
| 22 |
PAM Theragnostics
Developer of therapeutic and diagnostic tools for neurodegenerative disorders |
$1.7M | — | Series A | Series A Jan 2022 | — | 2020 | — |
| 23 |
Pantherna Therapeutics
Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery |
$4M | — | Seed | Seed Jul 2019 | 12 | 2017 | — |
| 24 |
Bomedus
Develops products to relieve acute and chronic pain |
$2.6M | — | Deadpooled | Series B Nov 2015 | 11 | 2012 | — |
| 25 |
CerboMed
A medical device company which engages in developing neuro therapy solutions. |
$2.6M | — | Series A | Series A Sep 2012 | 5 | 2005 | — |
| 26 |
Nocturne
Provider of medical image analysis platform |
$270.6K | — | Seed | Grant (prize money) Jun 2022 | 3 | 2016 | — |
| 27 |
CogniScent
Provider of AI-based platform for early detection of neurodegenerative diseases |
$355K | — | Deadpooled | Grant (prize money) 2020 | 2 | 2019 | — |
| 28 |
Localite
Developer of surgical navigation and planning systems |
$123.1K | — | Funding Raised | Grant (prize money) Oct 2022 | 15 | 1999 | — |
| 29 |
Hasomed
A portfolio of neurorehabilitation devices |
$610K | — | Funding Raised | Grant (prize money) Jan 2017 | 92 | 2014 | — |
| 30 |
Sonovum
Non-invasive diagnostics of brain disorders using ultrasound |
$110.2K | — | Public | Grant (prize money) Oct 2015 | 29 | 2011 | — |
| 31 |
Infinit Bio
Developer of psychedelic-based therapies for mental health |
— | — | Deadpooled | Seed Apr 2022 | 3 | 2021 | — |
| 32 |
Motognosis
Developer of motion analysis solutions to diagnose brain function and cognitive deficits |
— | — | Seed | Seed Jan 2021 | — | 2014 | — |
| 33 |
Portabiles HealthCare Technologies
Developer of medical products and services for Parkinson’s patient care |
— | — | Funding Raised | Grant (prize money) Jul 2020 | — | 2016 | — |
| 34 |
SeNostic
In vitro diagnostics for neurodegenerative diseases. |
— | — | Seed | Seed Jan 2016 | 11 | 2014 | — |
| 35 |
Predemtec
Solutions for the early detection of dementia |
— | — | Seed | Seed Jul 2014 | 3 | 2011 | — |
| 36 |
Phenox
Developer of medical devices for interventional neurology |
— | — | Acquired | Series A Aug 2010 | 240 | 2005 | — |
| 37 |
A2M Pharma
German, early stage drug development company focused on Neurodegenerative diseases. |
— | — | Deadpooled | — | — | 2009 | — |
| 38 |
Acandis
Developer of medical devices for hemorrhagic and ischemic stroke treatment |
— | — | Funding Raised | — | 170 | 2006 | — |
| 39 |
Apurano Pharmaceuticals
Provider of smart bio-nanotechnology pharmaceutical products for multiple diseases |
— | — | Unfunded | — | — | 2014 | — |
| 40 |
attyloid
Quantitative detection of single oligomers and aggregates for CNS disorders |
— | — | Unfunded | — | 3 | 2018 | — |
| 41 | Axaron Bioscience | — | — | Acquired | — | 70 | 1996 | — |
| 42 |
B. Braun Miethke
Provider of targeted drug delivery device in the field of neurosurgery |
— | — | Unfunded | — | — | 2017 | — |
| 43 |
Berlirem
Developer of pharmaceutical products for continuous parenteral application of Levodopa |
— | — | Unfunded | — | — | 2014 | — |
| 44 |
Brain Products
Provider of hardware and software for human brain research |
— | — | Unfunded | — | — | 2018 | — |
| 45 |
BrainRepair
Developer of stem-cell-based therapeutics for treating brain injury |
— | — | Unfunded | — | — | 2009 | — |
| 46 |
ceregate
CereGate a San Diego,CA-based developer of a a new software platform |
— | — | Private | — | 14 | 2019 | — |
| 47 |
DeepEn
Developer of hair-thin endoscopes for imaging brain diseases |
— | — | Unfunded | — | — | 2023 | — |
| 48 |
Diagenics Group SE
Developer of diagnostic products for cardiac and gynecological disorders |
— | — | Unfunded | — | — | 2002 | — |
| 49 |
DoNatur
Developer of small molecule based therapeutics for the treatment of arthritis-pain and back-pain |
— | — | Funding Raised | — | — | 1999 | — |
| 50 |
Dr. Langer Medical
Devices for intraoperative neurological monitoring and neurostimulation |
— | — | Unfunded | — | 45 | 1996 | — |
Vivoryon Therapeutics is developing therapeutic agents for treating age-related diseases. The company leading candidate is PQ912 is in phase 2a of the clinical trial and is for Alzheimer's disease and Cancer, other candidates of the company are PQxxx and PQ1565 which is in the preclinical stage and effective against cancer and other diseases. Theses are small molecule-based and inhibit QTCPL. The company has develope
Developer of therapeutics and diagnostics for neurodegenerative diseases. The company focuses on research and development of disease-modifying treatments. It offers diagnostic procedures for early detection of neurodegenerative conditions. The company’s research includes oligomer modulators and clinical studies.
Evanium is developing a selective alcohol antagonist. The company is developing the therapeutics which is a negative modulator of the GABAA receptor and can antagonize the effect of alcohol on the central nervous system antagonizes the effect of alcohol on the central nervous system.
Brainjo is an AI-based platform that provides cognitive training. The company tests the physical and cognitive performance of the individual and set personal goals. It creates a personal training plan for physical-mental training. It provides training like reaction training, neurofeedback, and brain jogging.
Developer of minimally invasive brain interfaces for mental health treatment. These devices utilize physiological mechanisms to address major depressive disorder. The technology integrates with biological systems to modulate neural activity for therapeutic purposes.
Provider of noninvasive neurotechnology and personalized mental healthcare platform. The organization develops and supplies digital therapy systems combined with clinical protocols and training for transcranial magnetic stimulation, neurofeedback, EEG, and related neurological assessment tools. It offers a software-based best practice platform that supports clinicians in delivering individualized care through integra
Manufacturer of cerebral protection device It produces a cerebral protection device for use during cardiac surgeries involving the left heart to prevent strokes. Their device consists of an implantable filter system that can be introduced into the aortic arch during minimally invasive procedures which prevent the migration of embolic particles into the cerebral vasculature which prevents strokes.
Developer of a digital drug to treat Alzheimer's disease. It offers Memory-Pacemaker a non-invasive, photonic neurostimulation to re-enable patients with Alzheimer's Disease to store and recall memories again.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geograph
Developer of targeted therapies for depression and other neuropsychiatric disorders. The company has machine learning-based tests to personalize the treatment of neuropsychiatric complications which include depression, stress, and sleep disorders.
Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies. They offer design, development, and manufacturing services for medical devices. The company provides cuff electrodes, grid electrodes, paddle and strip electrodes, and percutaneous electrodes. Services include electronics and software development, prototyping, testing, and validation. The Brain Interchange System is available
Probiodrug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. The company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiodrug as drug candidates for the treatment of major diseases such as Alzheimer's disease or chronic inflammatory disorders. The Company has a
HTGF
Kfw
Europa
EIC Fund
EQT
Life Sciences Partners
Bayern Kapital
BioVaria
Bmbf
German Accelerator
IBB Ventures
IBG Beteiligungsgesellschaft Sachsen-Anhalt
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-22.
_1537501792425.png){kind=logo}
_1580379092115.png){kind=logo}
